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Maternal serum alpha-fetoprotein (MSAFP) is in pregnancies whose early mid-trimester MSAFP
known to be elevated in fetal open neural tube values were greater than twice the median; these
defects (NTD) [5, 7, 21, 24]. It is used as an early infants were appropriate but not small for gesta-
screening method for this condition when meas- tional age.
ured between 15 and 20 weeks of gestation and is None of the reported studies has examined the
likelytobecomearoutinepartofprenatalcare.lt overall relationship, if any between early mid-
is also elevated in multiple pregnancies [23], fetal trimester MSAFP and neonatal birth weight and
demise [18], threatened abortion [22] and other gestational age. The purpose of this study is to
fetal abnormalities, such as omphalocele, fetal determine if such relationships exist and whether
bowel obstruction [6], congenital nephrotic syn- or not they may be useful in detecting risk for
drome [17], trisomy 13 with cystic hygroma and altered growth or preterm delivery.
TURNER'S syndrome [13]. In the non-pregnant
state, serum AFP is elevated in primary hepatoma
[1], embryonal cell carcinoma of the ovary [12],
ataxia telangectasia and hepatitis [19].
Elevated mid-trimester alpha-fetoprotein (MSAFP) - .. . . ,
 Λ ,, ,
. , * \ „ v ,, } 1 Matenals and methodsin women carrying single, anatomically and karyo-
typically normal fetuses has been found to precede Venous blood was obtained from patients referred
the birth of low birthweight infants. BROCK et al. for genetic counseling prior to clinically indicated
[4], found that the proportion of low birthweight amniocentesis between 15 and 20 weeks gestation
infants less than 2.5 kg was significantly increased in the period between January 1980 and Decem-
when early mid-trimester MSAFP was greater than ber 1982. Informed consents were obtained from
2.3 (x median value). WALD et al. [25], demon- all patients. Complete data including MSAFP
strated that pregnancies with early mid-trimester values, neonatal birthweight, and estimated gesta-
MSAFP greater than or equal to 3 (x median tional age at birth were available in 116 preg-
value), resulted in the birth of infants weighing on nancies. Indications for genetic counseling are
the average 357 gms less than the controls. Also, included in Tab. I. One hundred and ten karyo-
the gestational age at the time of birth was 8 days typically and anatomically singleton pregnancy
less than the controls. SMITH [20] on the other outcomes were evaluated; six cases were excluded
hand, found that a statistically significant increase because of fetal demise (3 cases), trisomy 21
in the number of infants weighing less than 2.5 kg (1 case), trisomy X (1 case), twins (1 case).
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Tab. I. Indications for genetic amniocentesis
Indication Number
Maternal age < 35 102
Family history of NTD 3
Family history of DOWN's Syndrome 3
Parental sickle cell disease 3
Family history of mental retardation 2
Previous sibling with chromosomal abnormality 1
Maternal anxiety 1
Major fetal anomalies by ultrasound 1
Total 116
MSAFP was determined by radioimmunoassay
(RIA) and values were expressed as multiples of
\ the median (MOM) [16].
Gestational age at amniocentesis was calculated
from ultrasonic examination of the biparietal
diameter and femur length. Gestational age at
birth was estimated using the BALLARD modifica-
tion of the DUBOWITZ examination of the neonate
[2]·
Statistical analysis utilizing polynomial and multi-
linear regression was performed to determine the
relationship of MSAFP values between 15 and
20 weeks gestation, expressed as multiples of the
median (MOM), to the neonatal birth weight,
gestational age at birth and birthweight adjusted
for gestational age. A p less than .05 was con-
sidered significant.
2 Results
The mean gestational age at the time of sampling
was 16.8 ±1.2 weeks; the mean gestational age at
birth was 39.6 ± 2 weeks; the mean birthweight
was 3436 ± 654 gms. The MSAFP values ranged
from .19-3.1 multiples of the median. These
values are presented in Tab. II in detail.
Using polynomial regression we found that,
according to the equation - Birthweigt (gms.)
= - 332 AFP + 3748, the birthweight decreased
322 grams for each one MOM increase of MSAFP.
For this relationship, R = .234 and p < .02. There
was no improvement in the strength of this rela-
tionship (or of any of the other tested relation-
ships) beyond the linear fit.
A relationship of MSAFP to birthweight could be
accounted for by an effect of pregnancy duration,
fetal growth or both. To examine this possibility,
multilinear regression analysis was utilized. It was
found that MSAFP values between 15 and 20
weeks gestation related to birthweight adjusted for
gestational age ten-fold more strongly (R2 = 6.3 %,
ρ < 0.01) as shown in Fig. 1 than to gestational age
alon (R2 = .6 %, NS). Gestational age at amnio-
centesis was unrelated to fetal growth or preg-
nancy duration.
3 Discussion
This study demonstrates that there is a definite
linear relationship between early mid-trimester
MSAFP values and fetal growth, a mainly third tri-
mester phenomenon. Early mid-trimester MSAFP
values were not significantly related to gestational
age at birth.
Our study differs from those previously reported
[3, 4, 20, 25], in that all babies were included, so
that any overall relationships could be detected,
rather than simply to correlate their birthweight
with early mid-trimester MSAFP values relating
elevated MSAFP values to low birthweight. The
majority of patients in this study were referrals
Tab. II. Values obstained in the current study
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Fig. 1. Relationship of MSAFP values expressed as MOM to birthweight adjusted for gestational age.
(40 patients from our institution) for genetic
counseling. They were, in general, not at increased
risk for intrauterine growth retardation (IUGR).
This is reflected in the distribution of their out-
comes — 85 appropriate for gestational age, 22
large for gestational age, and 3 small for gesta-
tional age.
The explanation for the key finding in this study
remains speculative AFP is a predominant protein
in fetal plasma and it reaches its highest concentra-
tion [9] at 12—15 weeks gestation. It is synthesized
in the fetal liver [8] and the embryonal sac [10]; it
passes by diffusion into the fetal urine and is
excreted into the amniotic fluid. Some of the
amniotic fluid AFP diffuses into the tnaternal
circulation through the amnion while some is
swallowed by the fetus. As pregnancy progresses,
an increasing portion of the maternal serum AFP is
derived by placental passage. While the amniotic
fluid AFP declines as gestation proceeds, the level
in maternal serum rises geometrically until 32
weeks when it begins to fall [9].
Nonetheless, the elevation of serum AFP in pri-
mary liver cancer in non-pregnant patients has
been attributed to its increased production from
undifferentiated cells [15]. Raised levels in non-
malignant liver disease during the recovery stages
seems to be associated with regeneration of the
liver cells; both in experimental liver damage in
mice and after cessation of alcohol intake in
cirrhotic patients, AFP levels have been found to
be elevated [4]. This might offer an explanation
for elevated early mid-trimester MSAFP and
altered fetal growth; the liver is the first organ to
be affected in growth retarded fetuses. This could
be associated with a protective mechanism, in
the form of multiplication or relatively undiffer-
entiated embryonic cells which would produce
increased amounts of AFP. This hypothesis could
and should be tested.
An alternative hypothesis to explain the relation-
ship between MSAFP and fetal growth could be
based on the observation of spontaneous fetal-
maternal hemorrhaging and elevated early mid-
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trimester maternal serum alpha-fetoprotein, as
reported by HAY [11]. We are currently examining
this possibility.
Regardless of the precise mechanism, it is reason-
able to conclude from the current results that
early mid-trimester MSAFP determinations, likely
to become a routine part of prenatal care for NTD
screening, may also be of assistance in identifica-
tion of fetuses at risk for altered growth. Early
mid-trimester MSAFP does not appear to aid in
the detection of preterm or postterm births. The
utility of maternal serum alpha-fetoprotein for the
antenatal detection of IUGR deserves further
study.
Summary
Early mid-trimester screening of maternal serum alpha-
fetoprotein (MSAFP) for the detection of neural tube
defects is becoming a routine part of obstetrical care. In
singleton pregnancies in the absence of fetal chromosomal
abnormalities and anatomical anomalies high levels of
AFP have been variably related to increased risk for low
birthweight infant outcome. The overall relationship, if
any, of maternal serum AFP to infant birthweight has,
however, not been previously characterized. Between 15
and 20 weeks gestation, MSAFP values were determined
for 110 women carrying single, anatomically and karyo-
typically normal fetuses. Statistical analysis utilizing
polynomial and multilinear regression was used to deter-
mine the relationship of early mid-trimester MSAFP first
to neonatal birthweight and then to gestational age
and birthweight adjusted for gestational age. For every
increase of one multiple of the median in MSAFP, neo-
natal birthweight fell 3 22 grams. This was accounted for
almost entirely by decreased fetal growth; early mid-
trimester MSAFP was linearly related to birthweight
adjusted for gestational age ten times more strongly than
to gestational age alone. The explanation for this relation-
ship remains speculative, but the utility of routine AFP
screening for the antenatal detection of intrauterine
growth retardation certainly deserves further study.
Keywords: Alpha-fetoprotein, birthweight, gestational age? intrauterine growth retardation.
Zusammenfassung
Alpha-Fetoproteinspiegel im mütterlichen Serum (MSAFP)
und fetales Wachstum
Die Alpha-Fetoproteinbestimmung zu Beginn des zweiten
Schwangerschaftstrimenon zwecks Diagnose von Neural-
rohrdefekten scheint zu einer Routinemaßnahme in der
Geburtshilfe zu werden. Bei Einlingsschwangerschaften
ohne chromosomale und morphologische Anomalien
wurden wiederholt hohe Alpha-Fetoproteinspiegel in
Zusammenhang mit einem erhöhten Risiko für ein niedri-
ges Geburtsgewicht gebracht. Wenn es überhaupt diesen
Zusammenhang zwischen AFP und kindlichem Geburts-
gewicht gibt, so ist er bislang nicht genauer charakteri-
siert. Wir bestimmten bei 110 Einlingsschwangerschaften
mit karyotypisch und morphologisch nonnalen Feten die
MS AFP-Werte zwischen der 15. und 20. Schwangerschafts-
woche. Mit Hilfe der statistischen Bearbeitung unter Ver-
wendung der polynomen und multilinearen Regressions-
analyse wollten wir erstens die Beziehung zwischen
MSAFP-Werten zu Anfang des zweiten Trimenons und
dem Geburtsgewicht erfassen. Zweitens sollte die Bezie-
hung zum Schwangerschaftsalter bzw. zum anhand des
geschätzten Geburtsgewichtes korrigierten Schwanger-
schaftsalter charakterisiert werden. Jeder Anstieg des
Medians der MSAFP-Werte um eine Einheit bedeutet eine
Reduzierung des Geburtsgewichts um 322 Gramm. Dies
wird nahezu vollständig durch ein herabgesetztes fetales
Wachstum erklärt. Die lineare Beziehung zwischen den
MSAFP-Werten und dem auf das Schwangerschaftsalter
bezogene Geburtsgewicht ist zehnfach strenger als im
Vergleich zum Schwangerschaftsalter allein. Der Hinter-
grund für diese Zusammenhänge ist unklar. Es sollten
jedoch weitere Untersuchungen zu der Fragestellung
durchgeführt werden, ob ein routinemäßiges AFP-Screen-
ing zur Erfassung einer intrauterinen Wachstumsretardie-
rung sinnvoll ist.
Schlüsselwörter: Alpha-Fetoprotein, Geburtsgewicht, Gestationsalter, intrauterine Wachstumsretardierung.
Resume
Alpha foeto-proteine serique materneüe (MSaFP) et crois-
sance totale
Le dosage de Talpha-foeto proteine serique maternelle
(MSaFP) au debut du second trimestre est devenu habi-
tuel dans la surveillance obstetricale afin de detecter les
defauts de fermeture du tube neural. Au cours des gros-
sesses uniques, en Tabsence d'anomalies anatomiques, des
taux eleves d'aFP ont ete de fagon variable consideres
comme temoins d'un risque eleve d'avoir un enfant de
faible poids de naissance. Cependant, la relation globale
entre maternelle serique et le poids de naissance de
Penfant, si eile existe, n'a pas ete caracjerisee anterieure-
ment. On a determine les valeurs de TMSaFP entre 15 et
20 semaines gestationnelles chez 110 femmes enceintes
d'un seul foetus, anatomiquement normal et avec un
caryotype normal. Afin de determiner la relation entre
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1'MSaFP au debut du second trimostrc et d'unc part le
poids de naissance et d'autre part I'fige gestationnel et le
ppids de naissance en fonction de Page gestationnel, on a
effcctuo une analyse statistiquc utilisant uno regression
polynomialc et multilinoairc. Le poids de naissance chute
de 322 grammes pour chaque augmentation d'un multiple
de la valour^ moyenne d'MSaFP. Ce fait a 6t6 justifio
presque enticrcinent pax une diminution de la croissance
fatale; le taux d'MSaFP du dobut de deuxiemc trimcstre
est correlc de faqon linoaire au poids de naissance corrigo
en fonction de 1'fige gestationnel scul. L'explication de
cette relation demeure speculative, muis Putilito d'un
dosage d'cxFP en routine pour la detection antenatale du
retard de croissance intra-uterin merite ä coup sur une
etude supplemental^.
Mots-clcs: Age gestationnel, -foeto-proteine, poids de naissance, retard de croissance intra-uterin.
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